Contribution of Gag and Protease to HIV-1 phenotypic drug resistance in pediatric patients failing Protease inhibitor-based therapy

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 2248-2256

  Giandhari, Jennifer ^a,b,f   Basson, Adriaan E ^a,b   Sutherland, Katherine ^c   Parry, Chris M ^d   Cane, Patricia A ^d   Coovadia, Ashraf ^b   Kuhn, Louise ^e   Hunt, Gillian ^a,b   Morris, Lynn ^a,b  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; STAVUDINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BINDING SITE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; EFFECTIVE CONCENTRATION; GENE EXPRESSION; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; IN VIVO STUDY; PEDIATRICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SITE DIRECTED MUTAGENESIS; TUBERCULOSIS; VIRUS GENE; VIRUS ISOLATION; VIRUS STRAIN; WILD TYPE; DRUG EFFECTS; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HIV INFECTIONS; INFANT; MALE; METABOLISM; MUTATION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VIROLOGY;

AMINO ACID SUBSTITUTION; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; GENE EXPRESSION; GENE PRODUCTS, GAG; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; LOPINAVIR; MALE; MUTAGENESIS, SITE-DIRECTED; MUTATION; PHENOTYPE; RITONAVIR; TREATMENT FAILURE;

EID: 84963732128     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02682-15     Document Type: Article

References (39)

1. Fun A, Wensing AM, Verheyen J, Nijhuis M. 2012. Human immunodeficiency virus Gag and protease: partners in resistance. Retrovirology 9:63. http://dx.doi.org/10.1186/1742-4690-9-63.
2. Department of Health. 2013. The South African antiretroviral treatment guidelines. Department of Health, Pretoria, South Africa.
3. Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM. 2008. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 47:566-569. http://dx.doi.org/10.1097/QAI.0b013e3181642257.
4. van Zyl GU, Rabie H, Nuttall JJ, Cotton MF. 2011. It is time to consider third-line options in antiretroviral-experienced paediatric patients? J Int AIDS Soc 14:55. http://dx.doi.org/10.1186/1758-2652-14-55.
5. WHO. 2013. Global update on HIV treatment 2013: results, impact and opportunities. WHO, Geneva, Switzerland.
6. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, Jean-Philippe P, McIntyre JA. 2008. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 359:2233-2244. http://dx.doi.org/10.1056/NEJMoa0800971.
7. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, Bwakura-Dangarembizi M, Chi BH, Musoke P, Kamthunzi P, Schimana W, Purdue L, Eshleman SH, Abrams EJ, Millar L, Petzold E, Mofenson LM, Jean-Philippe P, Violari A. 2010. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 363:1510-1520. http://dx.doi.org/10.1056/NEJMoa1000931.
8. Porter M, Davies MA, Mapani MK, Rabie H, Phiri S, Nuttall J, Fairlie L, Technau KG, Stinson K, Wood R, Wellington M, Haas AD, Giddy J, Tanser F, Eley B. 2015. Outcomes of infants starting antiretroviral therapy in Southern Africa, 2004-2012. J Acquir Immune Defic Syndr 69:593-601. http://dx.doi.org/10.1097/QAI.0000000000000683.
9. Gupta RK, Gibb D, Pillay D. 2009. Management of paediatric HIV-1 resistance. Curr Opin Infect Dis 22:256-263. http://dx.doi.org/10.1097/QCO.0b013e3283298f1f.
10. Iyidogan P, Anderson KS. 2014. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses 6:4095-4139. http://dx.doi.org/10.3390/v6104095.
11. Levison JH, Orrell C, Gallien S, Kuritzkes DR, Fu N, Losina E, Freedberg KA, Wood R. 2012. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One 7:e32144. http://dx.doi.org/10.1371/journal.pone.0032144.
12. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. 2011. Protease inhibitor resistance is uncommon in HIV-1 subtypeCinfected patients on failing second-line lopinavir/r-containing antiretroviral therapy in South Africa. AIDS Res Treat 2011:769627. http://dx.doi.org/10.1155/2011/769627.
13. Bartlett JA. 2013. Lack of protease inhibitor resistance following treatment failure-too good to be true? J Clin Invest 123:3704-3705. http://dx.doi.org/10.1172/JCI71784.
14. Orrell C, Levison J, Ciaranello A, Bekker LG, Kuritzkes DR, Freedberg KA, Wood R. 2013. Resistance in pediatric patients experiencing virologic failure with first-and second-line antiretroviral therapy. Pediatr Infect Dis J 32:644-647. http://dx.doi.org/10.1097/INF.0b013e3182829092.
15. Rabi SA, Laird GM, Durand CM, Laskey S, Shan L, Bailey JR, Chioma S, Moore RD, Siliciano RF. 2013. Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest 123:3848-3860. http://dx.doi.org/10.1172/JCI67399.
16. Siliciano JD, Siliciano RF. 2013. Recent trends in HIV-1 drug resistance. Curr Opin Virol 3:487-494. http://dx.doi.org/10.1016/j.coviro.2013.08.007.
17. Ali A, Bandaranayake RM, Cai Y, King NM, Kolli M, Mittal S, Murzycki JF, Nalam MN, Nalivaika EA, Ozen A, Prabu-Jeyabalan MM, Thayer K, Schiffer CA. 2010. Molecular basis for drug resistance in HIV-1 protease. Viruses 2:2509-2535. http://dx.doi.org/10.3390/v2112509.
18. Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X, Kräusslich H-G, Hance AJ, Clavel F, ANRS 109 Study Group. 2009. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog 5:e1000345. http://dx.doi.org/10.1371/journal.ppat.1000345.
19. Gupta RK, Kohli A, McCormick AL, Towers GJ, Pillay D, Parry CM. 2010. Full-length HIV-1 Gag determines protease inhibitor susceptibility within in-vitro assays. AIDS 24:1651-1655. http://dx.doi.org/10.1097/QAD.0b013e3283398216.
20. Verheyen J, Litau E, Sing T, Daumer M, Balduin M, Oette M, Fatkenheuer G, Rockstroh JK, Schuldenzucker U, Hoffmann D, Pfister H, Kaiser R. 2006. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther 11:879-887.
21. Kolli M, Stawiski E, Chappey C, Schiffer CA. 2009. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. J Virol 83:11027-11042. http://dx.doi.org/10.1128/JVI.00628-09.
22. Parry CM, Kohli A, Boinett CJ, Towers GJ, McCormick AL, Pillay D. 2009. Gag determinants of fitness and drug susceptibility in protease inhibitorresistant human immunodeficiency virus type 1. J Virol 83:9094-9101. http://dx.doi.org/10.1128/JVI.02356-08.
23. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, Rovenska M, de Jong D, Chappey C, Goedegebuure IW, Heilek-Snyder G, Dulude D, Cammack N, Brakier-Gingras L, Konvalinka J, Parkin N, Kräusslich HG, Brun-Vezinet F, Boucher CA. 2007. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 4:e36. http://dx.doi.org/10.1371/journal.pmed.0040036.
24. Fun A, van Maarseveen NM, Pokorna J, Maas RE, Schipper PJ, Konvalinka J, Nijhuis M. 2011. HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat. Retrovirology 8:70. http://dx.doi.org/10.1186/1742-4690-8-70.
25. Kolli M, Özen A, Kurt-Yilmaz N, Schiffer CA. 2014. HIV-1 proteasesubstrate coevolution in nelfinavir resistance. J Virol 88:7145-7154. http://dx.doi.org/10.1128/JVI.00266-14.
26. Li G, Verheyen J, Theys K, Piampongsant S, Van Laethem K, Vandamme AM. 2014. HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes. Retrovirology 11:79. http://dx.doi.org/10.1186/s12977-014-0079-7.
27. de Oliveira T, Engelbrecht S, Janse van Rensburg E, Gordon M, Bishop K, zur Megede J, Barnett SW, Cassol S. 2003. Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness? J Virol 77:9422-9430. http://dx.doi.org/10.1128/JVI.77.17.9422-9430.2003.
28. Giandhari J, Basson AE, Coovadia A, Kuhn L, Abrams EJ, Strehlau R, Morris L, Hunt G. 2015. Genetic changes in HIV-1 Gag-protease associated with protease inhibitor-based therapy failure in paediatric patients. AIDS Res Hum Retroviruses 31:776-782. http://dx.doi.org/10.1089/aid.2014.0349.
29. Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, Sherman G, Hunt G, Hu CC, Tsai WY, Morris L, Kuhn L. 2010. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA 304:1082-1090. http://dx.doi.org/10.1001/jama.2010.1278.
30. Taylor B, Hunt G, Abrams EJ, Coovadia A, Meyers T, Sherman G, Strehlau R, Morris L, Kuhn L. 2011. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses 27:945-956. http://dx.doi.org/10.1089/aid.2010.0205.
31. Reitz C, Coovadia A, Ko S, Meyers T, Strehlau R, Sherman G, Kuhn L, Abrams EJ. 2010. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis 201:1121-1131. http://dx.doi.org/10.1086/651454.
32. Sutherland KA, Mbisa JL, Cane PA, Pillay D, Parry CM. 2014. Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1. J Gen Virol 95(Pt 1):190-200. http://dx.doi.org/10.1099/vir.0.055624-0.
33. Ndung'u T, Renjifo B, Essex M. 2001. Construction and analysis of an infectious human immunodeficiency virus type 1 subtype C molecular clone. J Virol 75:4964-4972. http://dx.doi.org/10.1128/JVI.75.11.4964-4972.2001.
34. Parry CM, Kolli M, Myers RE, Cane PA, Schiffer C, Pillay D. 2011. Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity. Antimicrob Agents Chemother 55:1106-1113. http://dx.doi.org/10.1128/AAC.01228-10.
35. Koh Y, Das D, Leschenko S, Nakata H, Ogata-Aoki H, Amano M, Nakayama M, Ghosh AK, Mitsuya H. 2009. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother 53:997-1006. http://dx.doi.org/10.1128/AAC.00689-08.
36. Sutherland KA, Mbisa JL, Ghosn J, Chaix ML, Cohen-Codar I, Hue S, Delfraissy JF, Delaugerre C, Gupta RK. 2014. Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genes. J Antimicrob Chemother 69:3340-3348. http://dx.doi.org/10.1093/jac/dku296.
37. Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, Richards N, Hanlon MH, Porter DJT, Wrin T, Parkin N, Tisdale M, Furfine E, Petropoulos C, Snowden BW, Kleim J-P. 2002. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 76:7398-7406. http://dx.doi.org/10.1128/JVI.76.15.7398-7406.2002.
38. van Zyl GU, van der Merwe L, Claassen M, Cotton MF, Rabie H, Prozesky HW, Preiser W. 2009. Protease inhibitor resistance in South African children with virologic failure. Pediatr Infect Dis J 28:1125-1127. http://dx.doi.org/10.1097/INF.0b013e3181af829d.
39. Rosenbloom DI, Hill AL, Rabi SA, Siliciano RF, Nowak MA. 2012. Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med 18:1378-1385. http://dx.doi.org/10.1038/nm.2892.